CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells - PubMed (original) (raw)
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
M F Krummel et al. J Exp Med. 1996.
Abstract
While interactions between CD28 and members of the B7 family costimulate and enhance T cell responses, recent evidence indicates that the CD28 homologue CTLA-4 plays a downregulatory role. The mechanism by which this occurs is not clear, but it has been suggested that CTLA-4 terminates ongoing responses of activated T cells, perhaps by induction of apoptosis. Here we demonstrate that CTLA-4 engagement by antibody cross-linking or binding to B7 inhibits proliferation and accumulation of the primary T cell growth factor, IL-2, by cells stimulated with anti-CD3 and anti-CD28. This inhibition is not a result of enhanced cell death. Rather it appears to result from restriction of transition from the G1 to the S phase of the cell cycle. Our observation that upregulation of both the IL-2R alpha chain and the CD69 activation antigen are inhibited by CTLA-4 engagement supplies further evidence that CTLA-4 restricts the progression of T cells to an activated state. Together this data demonstrates that CTLA-4 can regulate T cell activation in the absence of induction of apoptotic cell death.
Similar articles
- CTLA-4 ligation blocks CD28-dependent T cell activation.
Walunas TL, Bakker CY, Bluestone JA. Walunas TL, et al. J Exp Med. 1996 Jun 1;183(6):2541-50. doi: 10.1084/jem.183.6.2541. J Exp Med. 1996. PMID: 8676075 Free PMC article. - Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells.
Chen W, Jin W, Wahl SM. Chen W, et al. J Exp Med. 1998 Nov 16;188(10):1849-57. doi: 10.1084/jem.188.10.1849. J Exp Med. 1998. PMID: 9815262 Free PMC article. - CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J. Carreno BM, et al. J Immunol. 2000 Aug 1;165(3):1352-6. doi: 10.4049/jimmunol.165.3.1352. J Immunol. 2000. PMID: 10903737 - CTLA-4 and T cell activation.
Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. Oosterwegel MA, et al. Curr Opin Immunol. 1999 Jun;11(3):294-300. doi: 10.1016/s0952-7915(99)80047-8. Curr Opin Immunol. 1999. PMID: 10375557 Review. - Regulation of T cell activation by CD28 and CTLA4.
Noel PJ, Boise LH, Thompson CB. Noel PJ, et al. Adv Exp Med Biol. 1996;406:209-17. doi: 10.1007/978-1-4899-0274-0_22. Adv Exp Med Biol. 1996. PMID: 8910687 Review.
Cited by
- Cancer immunotherapies: A hope for the uncurable?
Hamdan F, Cerullo V. Hamdan F, et al. Front Mol Med. 2023 Feb 17;3:1140977. doi: 10.3389/fmmed.2023.1140977. eCollection 2023. Front Mol Med. 2023. PMID: 39086690 Free PMC article. Review. - High expression of CCNB2 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in breast carcinoma.
Lu Z, Wang Z, Li G. Lu Z, et al. Heliyon. 2024 May 21;10(10):e31586. doi: 10.1016/j.heliyon.2024.e31586. eCollection 2024 May 30. Heliyon. 2024. PMID: 38831807 Free PMC article. - Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.
Pitts SC, Schlom J, Donahue RN. Pitts SC, et al. J Exp Clin Cancer Res. 2024 May 31;43(1):155. doi: 10.1186/s13046-024-03074-z. J Exp Clin Cancer Res. 2024. PMID: 38822401 Free PMC article. Review. - Cancer biotherapy: review and prospect.
Liu Q, Ma H. Liu Q, et al. Clin Exp Med. 2024 May 27;24(1):114. doi: 10.1007/s10238-024-01376-2. Clin Exp Med. 2024. PMID: 38801637 Free PMC article. Review. - Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.
Ma Y, Shi R, Li F, Chang H. Ma Y, et al. Cell Commun Signal. 2024 May 7;22(1):262. doi: 10.1186/s12964-024-01641-7. Cell Commun Signal. 2024. PMID: 38715122 Free PMC article. Review.
References
- J Immunol. 1980 Dec;125(6):2665-72 - PubMed
- Immunity. 1995 Jul;3(1):87-98 - PubMed
- Immunogenetics. 1981;14(1-2):53-61 - PubMed
- Proc Natl Acad Sci U S A. 1985 Feb;82(3):864-8 - PubMed
- Proc Natl Acad Sci U S A. 1989 Jun;86(11):4185-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous